Gregory Cheng

机构：Synertech PM (United States) · ORCID：0000-0001-9331-345X

发表论文 126 篇 · 总被引 10048 次 · h-index 38

代表论文

• Prediction for Progression Risk in Patients With COVID-19 Pneumonia: The CALL Score (2020 · Clinical Infectious Diseases · 被引 721)
• Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study (2020 · Journal of Hepatology · 被引 537)
• APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy (2021 · Hepatology International · 被引 178)
• Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation (2020 · Hepatology International · 被引 80)
• Effect of COVID-19 on patients with compensated chronic liver diseases (2020 · Hepatology International · 被引 69)
• APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024 (2024 · Hepatology International · 被引 61)